What the New Executive Order Means for Psychedelics
This image was generated by AI and may not depict real events.
A new executive order signed on April 18, 2026, aims to accelerate research and access to psychedelic treatments for mental health conditions. The order does not mean FDA approval or immediate availability of these treatments.
The US government has signed an executive order to accelerate research and access to psychedelic treatments for serious mental illnesses. The order, titled 'Accelerating Medical Treatments for Serious Mental Illness,' directs federal agencies to move quickly on research, review, and access pathways for investigational psychedelic treatments. It does not mean FDA approval or that these treatments are suddenly available. Many people living with depression, PTSD, and addiction are seeking better options, but hope and readiness are not the same thing. The order references ibogaine, which is still in clinical trials and has safety concerns. Psychedelic treatments are not equally far along in development, and practical challenges remain.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.